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SNPsaffectingdisease riskoften reside innon-coding
genomic regions. Here, we show that SNPs are highly
enriched at mouse strain-selective adipose tissue
binding sites for PPARg, a nuclear receptor for anti-
diabetic drugs. Many such SNPs alter binding motifs
for PPARg or cooperating factors and functionally
regulate nearby genes whose expression is strain
selective and imbalanced in heterozygous F1 mice.
Moreover, genetically determined binding of PPARg
accounts for mouse strain-specific transcriptional
effects of TZD drugs, providing proof of concept for
personalized medicine related to nuclear receptor
genomic occupancy. In human fat, motif-altering
SNPscausedifferentialPPARgbinding,provideamo-
lecular mechanism for some expression quantitative
trait loci, and are risk factors for dysmetabolic traits
in genome-wide association studies. One PPARg
motif-altering SNP is associated with HDL levels and
other metabolic syndrome parameters. Thus, natural
genetic variation in PPARg genomic occupancy de-
termines individual disease risk and drug response.
INTRODUCTION
A major unanswered question is how most genetic variation
causes phenotypic differences, as only a small fraction of sin-
gle-nucleotide polymorphisms (SNPs) affect protein sequence
(Shastry, 2002). Current genome-wide association studies
(GWAS) reveal a large gap between known causal genes and
the observed heritability of common diseases and treatment out-
comes (Sadee et al., 2014). Another limitation of GWAS is that
each locus nominates a large group of SNPs in linkage disequi-
librium, such that causal and neutral variants cannot easily be
distinguished. Non-coding SNPs in regulatory regionsmay affect
transcription factor (TF) binding and gene expression, thuscontributing to complex phenotypes like disease association
and response to drugs (Edwards et al., 2013).
There are examples of regulatory variants causing Mendelian
syndromes (De Gobbi et al., 2006; Smemo et al., 2012), but
such SNPs may be more likely to associate with complex non-
Mendelian diseases in GWAS (Sakabe et al., 2012). Overall, puta-
tive causal GWASSNPsclustermore in promoters and enhancers
than in exons (Andersson et al., 2014), and a recent effort to
computationally identify causal GWASSNPs for autoimmune dis-
eases found that90%were non-coding, with60% in distal im-
mune cell enhancers (Farh et al., 2015). A few specific examples
have emerged. The causal SNP for an LDL cholesterol and
myocardial infarction locus is a regulatory variant altering hepatic
SORT1 expression (Musunuru et al., 2010). Regulatory SNPs in
distantenhancers forMYC result inassociationswithmultiple can-
cers (Sur et al., 2013), and an intronic enhancer SNP in TCF7L2
may mediate type 2 diabetes (T2D) risk (Gaulton et al., 2010).
For the PPARG T2D locus, the causal SNP was thought to be a
coding Pro12Ala polymorphism, yet recent evidence has impli-
cated a tightly linked regulatory SNP (Claussnitzer et al., 2014).
PPARg provides an excellent system to study effects of regu-
latory variation on TF binding, gene expression, drug response,
and phenotype. PPARg is a nuclear receptor TF required for
adipocyte development (Wang et al., 2013) that activates many
adipocyte genes. PPARg is genetically implicated in metabolic
disease, both through the common SNP associated with T2D
(Altshuler et al., 2000) and also through rare ligand binding
domain mutations, causing an autosomal dominant syndrome
of lipodystrophic insulin resistance (Barroso et al., 1999). Since
variants affecting the PPARg TF itself have these consequences,
then genetic variation in key PPARg genomic binding sites may
similarly have metabolic effects.
PPARg is also the target of anti-diabetic thiazolidinedione
(TZD) drugs,which haveauniqueandpowerful insulin-sensitizing
effect, yet clinical use has declined due to concerns over side ef-
fects and adverse events (Soccio et al., 2014). Individuals differ in
drug response, and 20%–30% of diabetic patients fail to
respond to TZDs (Sears et al., 2009). Most pharmacogenomic
studies focus on coding or non-coding variants affecting theCell 162, 33–44, July 2, 2015 ª2015 Elsevier Inc. 33
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Figure 1. SNPs Genetically Determine
Mouse Strain-Selective PPARg Sites
(A) ChIP-seq in mouse WAT identified 35,000
PPARg sites, and the heat map shows 2,226 B6 or
129 strain-selective sites in three independent
experiments. High-confidence sites were 3-fold
strain selective in two, while highest-confidence
sites were in all three.
(B) For the five PPARg site classes, average
binding profiles are shown for the two inbred
strains (B6 red, 129 blue) and F1 progeny (green).
(C) For the five classes, occurrence of one or more
B6:129 SNPs in each site’s central 200 bp is
shown, with enrichment of SNPs in strain-selective
sites (*p < 0.0001 versus non-selective sites by
Chi-square test).
(D) In F1 ChIP-seq, allelic imbalance was assayed
in binding sites with SNPs (*p < 0.0001 versus non-
selective sites by Mann-Whitney test, two-tailed).
See also Figure S1 and Table S1.drug target itself or drug-metabolizing enzymes and transporters
(Mizzi et al., 2014). However, regulatory variants may potentially
alter downstream transcriptional effects of drugs, either indirectly
after signal transduction from a cell surface receptor or directly in
the case of DNA-binding nuclear receptors like PPARg.
Here, we set out to determine whether non-coding regulatory
variation could affect PPARg genomic occupancy and whether
such SNP-dependent binding could affect gene expression,
drug response, and metabolic phenotype. Chromatin immuno-
precipitation followed by deep sequencing (ChIP-seq) was
used to define genetically determined variation in PPARg sites
genome wide in white adipose tissue (WAT). In mice, sites with
inbred strain-selective PPARg genomic occupancy were highly
enriched for SNPs, and in heterozygous F1 mice, these SNPs
had allelic imbalance in PPARg binding. These SNPs often
altered TF motifs—not only motifs for PPARg, but also motifs
for other, cooperating TFs. Importantly, some strain-selective
binding sites were functional regulating nearby gene expression
inWAT, both basal and TZD stimulated. Similar studieswere per-
formed in human WAT, in whom SNPs also led to imbalanced
PPARg binding. Remarkably, these human SNPs were enriched
in WAT expression quantitative trait loci (eQTLs) as well as in re-34 Cell 162, 33–44, July 2, 2015 ª2015 Elsevier Inc.gions linked to metabolic disease in
GWAS. Thus, variable PPARg occupancy
due to SNPs determines nearby gene
activation by PPARg and its ligands, and
these effects may underlie genetic differ-
ences in metabolic phenotypes and drug
responses.
RESULTS
Genomic Binding of PPARg in
Mouse Fat Is Strain Selective and
Driven by SNPs
ChIP-seq was performed in WAT from
two inbred mouse strains, C57Bl/6J (B6)and 129S1/SvImJ (129), which differ in susceptibility to obesity
and insulin resistance (Almind and Kahn, 2004). Since highly
polymorphic 129 sequencing readsmay not align to the B6 refer-
ence genome, the SNP-sensitive alignment tool GSNAP (Wu and
Nacu, 2010) was used to eliminate alignment bias and identify
truly strain-selective binding (Figures S1A and S1B). Three inde-
pendent ChiP-seq experiments were performed (Table S1),
allowing identification of strain-selective sites at high confidence
(3-fold strain difference in reads in at least two out of three exper-
iments) and highest confidence (all three, Figure 1A). Average
peak heights in F1 intercross progeny were intermediate be-
tween parents, while nonselective sites were equal in all three
(Figure 1B), indicating that strain selectivity of adipose genomic
PPARg occupancy was genetically determined. Of note, while
WAT PPARg cistromes include contributions of other cell types
that express PPARg, such as resident macrophages, the great
majority of sites overlapped with those in 3T3-L1 adipocytes,
but not with previously reported macrophage-selective sites
(Lefterova et al., 2010), thus likely representing adipocyte bind-
ing sites.
The B6 and 129 genomes differ by 5.3 million SNPs (Keane
et al., 2011), and strain-selective sites were highly enriched for
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Figure 2. PPARg Binding Is Altered by SNPs
Affecting Motifs for PPARg or Other TFs
(A) Consensus motif logos for the four top-scoring
motif families found in PPARg binding regions, with
Cistrome identifiers and Z scores.
(B) Strain selectivity of PPARg binding sites at
motif-altering SNPs divided into four classes
based on size of the allelic effect on consensus
motif agreement.
(C–E) The same analysis for C/EBP, NFI, or GR
motif-altering SNPs.
The difference between SNPs with large and min-
imal motif effects was p < 0.0001 in (B) and (C), p =
0.0026 in (D), and p = 0.039 in (E) (Chi-square test).
See also Figures S2 and S3 and Table S1.occurrence of SNPs (Figure 1C). Notably, SNPs falling in B6- or
129-selective sites showed PPARg binding allelic imbalance in
F1 WAT favoring the allele with better parental binding, whereas
SNPs in non-selective sites showed equal representation of both
alleles (Figure 1D). F1 imbalance shows that cis-acting elements
determine PPARg occupancy, as selectivity is evident even
when two alleles are in the same nucleus.
To further validate cis-acting PPARg site SNPs, ChIP-seq was
performed in 3T3-L1 adipocytes, a cell line derived from outbred
NIH Swiss albino mice (Todaro and Green, 1963) and thus het-
erozygous at many loci. In these cells, PPARg bound at
9,000 sites of B6:129 SNPs, and importantly, at least 18%
were heterozygous (Figure S1C). At heterozygous sites where
PPARg binding was strain selective in B6 versus 129 WAT, the
predicted allelic imbalance in binding was observed in 3T3-L1
adipocytes (Figure S1D). This is similar to F1 mice and confirms
the powerful effect of cis-acting SNPs on PPARg genomic
binding.
SNPs Alter TF Motifs to Cause Strain-Selective PPARg
Binding
PPARg binds DNA at direct repeat 1 (DR1) motifs both in vitro
(Tontonoz et al., 1994) and in 3T3-L1 adipocytes (Lefterova
et al., 2008; Nielsen et al., 2008), and this was the topmotif found
in WAT PPARg sites (Figure 2A). To test whether DR1-altering
SNPs cause strain-selective binding, all polymorphic DR1motifs
in PPARg binding regions were identified and assigned motif
scores, such that the B6:129 score ratio indicated strain differ-
ence in consensus motif agreement. SNPs with large effects
on PPARg/DR1 motifs (ratio >16) were highly likely to show se-Cell 162,lective binding in the strain with the stron-
ger motif and were unlikely to be selective
for the opposite strain (Figure 2B). This
discrimination was apparent even when
SNPs had medium (8- to 16-fold) or small
(2- to 8-fold) motif effects but effectively
lost when SNPs had minimal effects (<2-
fold). While this analysis used thresholds
for motif effects and binding difference,
the same pattern emerged in a quantita-
tive scatterplot analysis correlating bind-
ing ratio versus motif ratio (Figure S2A).This approach relies on natural B6:129 genetic variation at
PPARg motifs but can be extended to other variants. For
instance, 3T3-L1 PPARg sites have 936 heterozygous SNPs
that are non-polymorphic between B6 and 129, and when these
SNPs altered PPARg/DR1 motifs, there was the predicted allelic
imbalance in PPARg occupancy (Figure S2B).
Individual nucleotide substitutions at each position of the DR1
motif (Figure S2C) were interrogated for PPARg occupancy ef-
fects. Overall, this strongly validated the motif ratio approach,
though there were informative exceptions where SNPs at some
locations had large occupancy effects despite apparently small
motif effects (Figures S2D–S2F). This reinforces a key point
about consensus ChIP-seq motifs: they reflect nucleotide fre-
quencies at motifs actually bound by the TF but may not neces-
sarily represent the strongest binding version of the motif. Also,
in addition to the core DR1 motif, three upstream bases also
determined PPARg occupancy (Figure S2G), confirming in vivo
the importance of 50 flanking sequence as reported in prior
in vitro studies (Juge-Aubry et al., 1997) and the X-ray crystal
structure (Chandra et al., 2008). Finally, the most drastic effects
on DR1motifs and PPARg binding occurred whenmultiple SNPs
altered the same motif (Figure S2H).
PPARg often binds DNA in close proximity to C/EBP TFs, and
the two facilitate each other’s binding by assisted loading (Mad-
sen et al., 2014). Consistent with other reported PPARg cis-
tromes (Lefterova et al., 2008; Nielsen et al., 2008), at WAT
PPARg sites, the top non-DR1 motif was for C/EBP (Figure 2A).
As with DR1, SNPs with large C/EBP motif effects caused the
predicted strain selectivity in PPARg occupancy (Figure 2C). In
addition to PPARg and C/EBP, a motif for the nuclear factor I33–44, July 2, 2015 ª2015 Elsevier Inc. 35
(NFI) family was also enriched at PPARg binding sites, consistent
with previous reports (Rajakumari et al., 2013). SNPs with large
NFI motif effects also gave strain selectivity in PPARg binding
(Figure 2D), indicating that an NFI TF can modulate PPARg
genomic binding in vivo. Thus, in addition to the well-known
PPARg-cooperating factor C/EBP, this SNP-based method
can also suggest functional relevance for novel candidate TFs.
The next highest motif found in PPARg sites was a glucocorti-
coid receptor (GR) motif, and SNPs altering this inverted repeat 3
(IR3) motif affected PPARg occupancy (Figure 2E). The effect of
IR3 motifs was independent, as an IR3 motif SNP never also
affected an overlapping DR1. GR plays a major role in adipocyte
biology (Steger et al., 2010). GR ChIP-seq performed in WAT
from B6 and 129 mice revealed strain-selective GR binding (Fig-
ure S3A) at sites highly enriched for SNPs (Figure S3B), and
SNPs in GR motifs had predicted effects on GR occupancy (Fig-
ure S3C). Moreover, the majority of PPARg binding sites in WAT
are also occupied by GR, and hundreds of sites had high-confi-
dence strain-selective binding of both factors (Figure S3D).
Many had motif-altering SNPs in PPARg, GR, or C/EBP motifs,
and all three types of SNPs could mediate strain-selective bind-
ing of both PPARg and GR (Figures S3E and S3F). Therefore,
SNPs altering PPARg motifs not only affect PPARg occupancy,
but also binding of other TFs likeGR. Conversely, PPARg binding
can be altered by SNPs in PPARg motifs as well as motifs for
other TFs, showing the powerful effect of motif SNPs on cooper-
ative binding of multiple TFs.
Selective sites with SNPs but not identifiable motifs (Fig-
ure S3G), may be due to SNPs affecting degenerate or non-
consensus motifs for these TFs or other TF motifs, yet many
strain-selective sites are non-polymorphic over 200 bp. Such un-
explained strain-selective sites, with or without SNPs, may result
from long-range interactions with other sites in the same locus,
and this is consistent with the observed clustering of both B6-
and 129-selective binding sites near other sites selective for
the same strain (Figure S3H).
Strain-Selective PPARg Binding Functions to Modulate
Nearby Gene Expression
Thegreatmajority ofPPARg sites, including thegenetically deter-
mined sites defined here, reside outside of promoters >5 kb from
transcription start sites (TSSs). The function of sites as enhancers
correlates with occupancy of cofactors such as Med1 and p300,
aswell aswith transcription of enhancerRNA (eRNA) identified by
global run-on sequencing (GRO-seq) (Hah et al., 2013; Step et al.,
2014). GRO-seqwas performed inWAT fromB6mice, and eRNA
was quantified at PPARg sites. High eRNA transcription in B6
WAT was present at 18% of B6-selective sites, a significant
3-fold enrichment versus the 129-selective siteswith little PPARg
binding in B6mice, themajority of which had no detectable eRNA
transcription (Figure 3A). Thus, strain-selective PPARg binding
in WAT correlated with functional enhancer activity defined
by eRNA transcription. Moreover, ChIP-seq for coactivators in
3T3-L1 adipocytes (Step et al., 2014) revealed imbalanced occu-
pancyof p300 (Figure 3B) andMed1 (FigureS4A) at heterozygous
sites with the same imbalance in PPARg binding. Thus, allele-
selective PPARg occupancy robustly predicts cofactor occu-
pancy and differential enhancer function.36 Cell 162, 33–44, July 2, 2015 ª2015 Elsevier Inc.To test for function of strain-selective PPARg sites in gene
regulation, RNA-seq was performed in four separate experi-
ments using WAT from B6 and 129 mice (Table S2), revealing
432 genes with consistently higher expression in one strain (Fig-
ure 3C). RNA-seq was also performed in WAT from F1mice, and
genes with strain-differential expression showed the predicted
imbalanced expression in F1s, indicating cis effects (Figure S4B).
Strain differences in gene expression observed inWATwere also
found in primary adipocytes differentiated in cell culture (Fig-
ure S4C), further supporting genetic determination.
To integrate strain-differential gene expression with PPARg
binding, we identified the nearest strain-selective site within 50
kb in either direction from each TSS. For genes with B6-higher
expression, the nearest selective PPARg site was B6 selective
four times as often as 129 selective (Figure 3D). Conversely, a
5-fold enrichment for 129 selectivity of the nearest PPARg site
was observed for genes whose expression was higher in 129
WAT. By contrast, strain-similar genes were equally unlikely to
be near to B6- or 129-selective sites. There was also a marked
effect of distance, such that, if a strain-differential gene TSS
was within 5 kb of the strain-selective site, gene expression
and PPARg binding nearly always favored that same strain (Fig-
ure S4D). If the nearest strain-selective site was 5–50 kb away,
there was 2-fold same-strain preference for gene expression,
but this was lost for distances 50–100 kb. The consistent direc-
tion of effects and their proximity dependence strongly suggest
that PPARg binding is causing differential gene expression. For
example, Sgcg expression is much higher in 129 WAT, and in
its first intron 600 bp from the TSS lies a 129-selective PPARg
site (Figure 3E) with a 129-stronger DR1motif SNP (Figure 3F). In
F1 WAT, expression is intermediate, with PPARg binding and
gene expression both demonstrating allelic imbalance highly fa-
voring 129 alleles. Although no characteristic of strain-selective
PPARg binding was fully predictive of differential gene expres-
sion, sites with strain selectivity in both binding and nearest
gene expression were, on average, stronger (Figure S4E), nearer
to the gene’s TSS (Figure S4F), associated with fewer nearby
and potentially redundant sites (Figure S4G), and enriched for
a helix-loop-helix TF-binding motif (Figure S4H) compared to
control sites (non-selective or strain selective without differential
nearest gene expression).
Functional PPARg site SNPs have potentially powerful appli-
cations to genetic studies. B6 and 129 mice differ in their sus-
ceptibility to obesity, and several quantitative trait loci (QTLs)
for this phenotype have been mapped (Lin et al., 2013). One
effort used computational tools to narrow QTL intervals (Su
et al., 2008), and within these we find five cases of strain-selec-
tive WAT gene expression attributable to PPARg binding
(Figure S5A). For instance, the Zdhhc2 gene encodes a palmi-
toyltransferase, and a 129-selective PPARg site is in a nearby
gene intron, with a DR1 motif-altering SNP favoring 129 (Figures
S5B and S5C). Zdhhc2 expression is 129-higher, and there is
also the predicted F1 imbalance in expression and PPARg bind-
ing. The PPARg site was validated by ChIP and quantitative PCR
showing high binding in 129, absent binding in B6, and interme-
diate binding in F1 WAT (Figure S5D). Furthermore, an allelic
imbalance assay on the F1 ChIP PCR product confirmed the
imbalance observed by ChIP-seq (Figure S5E). Thus, genetically
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Figure 3. Mouse Strain-Selective PPARg Sites Drive Differential WAT Gene Expression
(A) eRNA transcription in B6 WAT was measured by GRO-seq. By Chi-square test, p < 0.0001 for eRNA distribution, enriched in B6-selective sites.
(B) 373 SNPs inmouse 3T3-L1 adipocytes had adequate read depth (10+) in both PPARg and p300ChIP-seq, and allelic imbalance in p300 occupancy correlated
with imbalance in PPARg occupancy (linear regression r2 = 0.4 and p < 0.0001 for a non-zero slope). Inset shows that, at 2-fold threshold, 60% of SNPs with
imbalanced PPARg binding had p300 imbalance in the same direction, while only 3% had p300 imbalance in the opposite direction.
(C) Four RNA-seq experiments identified 13,000 genes expressed in WAT, and 432 genes showed significant strain-differential expression >1.5-fold in at least
three experiments.
(D) For the three gene classes, the nearest strain-selective binding site within 50 kb of the TSS was identified, demonstrating that strain-differential genes enrich
for sites selective for the same strain. By Chi-square test, p < 0.0001 for strain-similar versus B6- or 129-higher and for B6- versus 129-higher.
(E) Representative RNA-seq and ChIP-seq browser tracks are shown at the Sgcg gene, with 129-higher expression and a 129-selective PPARg site (yellow).
(F) The consensus PPARg/DR1motif logo is shown above themotif sequences in both strains at the Sgcg binding site, with SNP alleles colored and showing their
difference in motif agreement.
See also Figures S4 and S5 and Table S2.
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Sites Drive Differential Gene Activation by
Rosiglitazone
(A) RNA-seq identified rosi-regulated genes in
WAT, and the heatmap shows those with statisti-
cally significant increases in both strains (both
EDGEMp< 0.001) versus only one (p < 0.001 but p
> 0.01 in the other strain).
(B) For the three classes of genes, the nearest
strain-selective binding site within 50 kb of the TSS
was identified. By Chi-square test, p < 0.01 for B6-
only versus 129-only, and p < 0.05 for the overall
distribution.
(C–E) (C) The gene Abhd3 was rosi-up only in 129
WAT. A 129-selective PPARg site (yellow) is up-
stream of the Abhd3 TSS (D), with a motif-altering
SNP favoring the 129 allele (E).
(F) In 3T3-L1 adipocytes, PPARg ChIP-seq
showed two sites near theDhrs9 TSS (*), each with
a heterozygous central SNP imbalanced favoring
the reference allele by 3- to 4-fold. GRO-seq
showed a significant 40% rosi induction of posi-
tive-strand transcription of Dhrs9, with 50 hetero-
zygous SNPs in the gene body.
(G) Counting reference and other alleles at these
SNPs showed baseline imbalance favoring refer-
ence alleles and that rosiglitazone selectively
activated only the reference haplotype.
(H) At these SNPs, rosi significantly increased the
average amount of imbalance.
(C and H) Mean and SEM. ***p < 0.0001, **p < 0.01,
*p < 0.05; NS, not significant; unpaired t test, two-
tailed).
See also Figure S6 and Table S2.determined adipose PPARg binding that affects gene expres-
sion nominates mechanistic candidates for several mouse
obesity QTLs.
Strain-Selective PPARg Binding Mediates Differential
Responses to Anti-diabetic Drugs
Rosiglitazone (rosi) is an anti-diabetic TZD drug that functions as
a high-affinity activating ligand for PPARg (Lehmann et al., 1995).
To determine whether genetic differences in PPARg binding
affect TZD response, B6 and 129 mice were treated with rosi
for 2 weeks, and then RNA-seq of WAT was performed (Table
S2). Rosi upregulated (Figure 4A) and downregulated (Fig-
ure S6A) genes were classified by statistical significance in
both strains versus B6 only or 129 only. Integration of these
genes with nearby strain-selective PPARg binding revealed
that genes rosi-up only in B6 mice were much more likely be
near B6-selective sites, and genes that were rosi-up only in
129 mice likewise showed more nearby 129-selective sites (Fig-
ure 4B). By contrast, there was no such discrimination in four
control gene classes: those rosi-up in both strains were equally
likely to be near B6- and 129-selective sites (Figure 4B), as
were all groups of rosi-down genes (Figure S6B). This latter result
is remarkably consistent with the recent finding that adipocyte38 Cell 162, 33–44, July 2, 2015 ª2015 Elsevier Inc.gene repression by rosi is unrelated to nearby PPARg binding
(Step et al., 2014). As an example, the Abhd3 gene, encoding
a phospholipid lipase (Long et al., 2011), was rosi-up by 2-fold
only in 129 mice (Figure 4C), consistent with an upstream 129-
selective PPARg site (Figure 4D) with a 129-stronger DR1
motif-altering SNP (Figure 4E). Other examples of strain-selec-
tive rosi-induced genes are shown in Figure S6C. Allele-depen-
dent response to rosi was also measured in 3T3-L1 adipocytes
by analyzing GRO-seq data (Step et al., 2014) for allelic imbal-
ance in gene body transcription. The rosiglitazone-induced
gene Dhrs9 has two haplotypes (reference and other) in 3T3-L1
cells, with 50 heterozygous SNPs in the gene (Figure 4F). In the
absence of rosi, these SNPs showed imbalanced transcription
favoring reference alleles (Figure 4G). Rosi elicited a selective in-
crease in transcription of reference, but not other alleles, and
thus significantly increased the imbalance (Figure 4G and 4H).
This haplotype-selective effect of rosi on Dhrs9 transcription
correlated with PPARg occupancy, as two sites near the TSS
harbor SNPs, with imbalanced PPARg binding strongly favoring
reference alleles (Figure 4F). These data demonstrate the phar-
macogenomic role of regulatory SNPs in determining transcrip-
tional response to a drug, in this case by altering PPARg genomic
binding.
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Figure 5. HumanMotif-Altering SNPs Affect
PPARg Occupancy and Nearby Gene
Expression
Human PPARg sites were found by ChIP-seq in
WAT from five subjects, and SNPs in these sites
were identified that altered PPARg/DR1 or C/EBP
motifs.
(A and B) (A) PPARg motif-altering SNPs hetero-
zygous in one or more subjects were assessed for
2-fold allelic imbalance in ChIP-seq reads,
demonstrating that SNPs with larger motif effects
showed enrichment for higher PPARg binding to
the stronger motif allele. (B) The same analysis for
C/EBP motif-altering SNPs, which also affected
PPARg binding. By Chi-square test, the difference
between SNPswith large andminimalmotif effects
was p = 0.0002 in (A) and p = 0.002 in (B).
(C) Motif-altering SNPs were interrogated for ef-
fects on nearby gene expression in human WAT
eQTLs, and the best candidates with large motif
effects or imbalance in heterozygotes (as in A
and B) showed significant enrichment for eSNPs.
(D) For PPARg or C/EBP motif-altering SNPs with
eQTLs, the direction of association was tested,
and for the best candidates, the stronger motif
alleles were associated with higher gene expres-
sion. **p < 0.01, *p < 0.05 by Fisher’s Exact Test,
one-tailed.
See also Table S3.Motif-Altering SNPs Determine PPARg Occupancy and
Gene Expression in Human Fat
Humans are outbred, and any two unrelated individuals differ at
SNPs in 0.1% of the genome (Shastry, 2002), similar to the
difference between B6 and 129 mice. The above mouse find-
ings are not directly applicable to humans, since the great ma-
jority of adipocyte PPARg sites are not retained at syntenic
genomic positions between the species (Mikkelsen et al.,
2010; Soccio et al., 2011), and entirely different SNPs exist,
as they arose after speciation. Therefore, to determine the ef-
fects of SNPs on PPARg genomic occupancy, ChIP-seq was
performed on human subcutaneous adipose tissue from five
individuals (Table S3). SNPs were identified based on three
criteria: (1) annotated in dbSNP141 with minor allele frequency
>1%, (2) located in a PPARg binding site identified by ChIP-seq
in one or more subjects, and (3) altered in an identifiable PPARg
or C/EBP motif. To test for effects of motif alterations, a subset
of SNPs was identified as heterozygous in at least one subject,
as defined by detection of both alleles in ChIP-seq reads;
imbalanced PPARg binding in heterozygous subjects was
investigated by the same method used in F1 mice and 3T3-
L1 cells. Remarkably, and similar to mouse, human SNPs
altering motifs for PPARg (Figure 5A) or C/EBP (Figure 5B) led
to imbalanced binding in heterozygotes favoring the alleles
with stronger motifs. Thus, motif-altering SNPs determine
PPARg binding in human fat. Indeed, this effect was sizable
even though heterozygous cases with 100% imbalance, which
appear homozygous in the ChIP-seq data, could not be identi-
fied by this analysis.To test for function regulating nearby human genes, all candi-
date PPARg site motif-altering SNPs (regardless of heterozygos-
ity) were integrated with human eQTLs identified in fat biopsies
from 1,381 Finnish men in the METSIM cohort (Stanca´kova´
et al., 2012). These subjects had genotyping and adipose gene
expression analyses, and cis eQTLs fell within 1 Mb of a gene
and were significantly associated with its expression level (see
Supplemental Experimental Procedures). Within each eQTL,
the expression SNP (eSNP) was defined as most significantly
associated and thus most likely to be causal. There was a signif-
icant 3-fold enrichment of eSNPs in strong candidate motif-
altered SNPs relative to an internal control set of PPARg site
SNPs with only minimal motif effects (Figure 5C). SNPs with
small or medium motif effects showed intermediate 2.3-fold
enrichment, while the strongest candidate PPARg site SNPs
(those from Figures 5A and 5B showing imbalance in heterozy-
gous subjects favoring the stronger motif) were dramatically
and significantly enriched 7-fold for eSNPs (Figure 5C).
The direction of each eQTL was tested to determine whether
the strongermotif allele was associated with higher gene expres-
sion. For all SNPs in the eQTL data set, there was an even distri-
bution with 50.09% of reference alleles positively associated
with expression. Analysis of PPARg and C/EBP motif-altering
eSNPs revealed 70%–80% positive eQTL association for those
strongest candidate SNPs with observed imbalance in heterozy-
gotes (Figure 5D). By contrast, control eSNPs with minimal
motif effects showed the 50% positive association expected
by chance, while greater motif changes led to more positive as-
sociation with gene expression, strongly indicating causalityCell 162, 33–44, July 2, 2015 ª2015 Elsevier Inc. 39
AC
D E
B Figure 6. Human TMEM170B Gene Expres-
sion Driven by a Polymorphic PPARg Site
(A) In 23 subjects, the G:A eQTL SNP rs568867
was genotyped and WAT TMEM170B gene
expression was measured by Q-RT-PCR, vali-
dating genotype effects on expression (*p < 0.05
versus G/A by Mann-Whitney test).
(B) Murine 3T3-L1 or human SGBS cultured cells
were differentiated to adipocytes and treated with
rosiglitazone, with effects on TMEM170B gene
expression.
(C) Location of rs568867 PPARg motif-altering
SNP and aweakly linked (r2 = 0.513) SNP rs295051
in the mRNA 30 UTR.
(D) ChIP allelic imbalance assay in a G/A hetero-
zygous subject.
(E) Allelic imbalance in TMEM170B mRNA was
dependent on the rs568867 PPARg site genotype.
(B, D, and E) Mean and SEM; ***p < 0.0001, **p <
0.01, *p < 0.05; t test, two-tailed, unpaired.(Figure 5D). Based on interrogation of this large and powerful
eQTL data set, motif-altering SNPs affecting PPARg occupancy
are functional in determining the expression of nearby genes in
human fat.
For example, rs568867 is a highly significant eSNP for
TMEM170B gene expression (odds ratio 2.25, p = 3.3e-86),
and higher expression with the G allele was confirmed in fat
biopsies from 23 human subjects (Figure 6A). TMEM170B
encodes an uncharacterized transmembrane protein, and its
mRNA is strongly induced during mouse and human adipocyte
differentiation (Figure 6B), consistent with PPARg gene regula-
tion. The SNP falls in a PPARg site 12 kb upstream, in a DR1
with the G allele giving a stronger motif (Figure 6C), and ChIP
from a heterozygous subject confirmed selective PPARg binding
to the G allele (Figure 6D). Furthermore, an exonic SNP in the
TMEM170B 30 UTR allowed measurement of allelic imbalance
in mRNA expression. Eleven subjects were heterozygous for
this mRNA SNP, and imbalanced TMEM170B expression was
only observed in those three subjects G/A heterozygous at the
PPARg binding site SNP (Figure 6E). This correlation is highly40 Cell 162, 33–44, July 2, 2015 ª2015 Elsevier Inc.suggestive that imbalanced PPARg bind-
ing upstream of TMEM170B causes
imbalanced gene expression, and other
human regulatory SNPs likewise affect
PPARg binding and function.
SNP-Dependent PPARg Binding
Underlies Human Metabolic
Phenotypic Differences
Human PPARg site motif-altering SNPs
were interrogated in published GWAS
meta-analyses for eight metabolic traits
(see Supplemental Experimental Proce-
dures). SNPs that altered PPARg or
C/EBP motifs in PPARg sites were highly
enriched among SNPs associated with tri-
glyceride (TG) and HDL cholesterol (HDL)levels (Figure 7A). For TG, the odds ratio was 1.84 (95% confi-
dence interval of 1.27–2.66), and for HDL the odds ratio was
1.76 (1.22–2.56). In both cases, this nearly 2-fold enrichment
was beyond that expected by chance, even accounting for multi-
ple testing.
Since PPARg site motif-altering SNPs are enriched for dyslipi-
demia trait associations, some may be mechanistically impli-
cated. We focused on an HDL-associated PPARgmotif-altering
C:T SNP (rs392794), for which the T allele favors PPARg binding
(Figure 7B). There was significantly higher PPARg-dependent
activation of a reporter with a T allele (31-fold) versus the C allele
(7-fold, Figure 7C). The T allele that gives higher PPARg tran-
scriptional activity is associated with lower HDL, and this associ-
ation reached genome-wide significance at p = 8.1e-09 (below
the standard threshold of p = 5e-08). This novel association is in-
dependent of a reported dyslipidemia locus 55 kb away
marked by another SNP (Willer et al., 2013) which is not tightly
linked (Figure 7D, red arrow indicates a recombination hot spot
between the SNPs). Furthermore, conditional analysis to remove
the effects of the previously reported SNP showed that the
AD E
B C Figure 7. PPARg Site Motif-Altering SNPs
Affect Human Metabolic GWAS Traits
(A) Candidate human SNPs in PPARg sites with
more than minimal effects on PPARg or C/EBP
motifs were interrogated for enrichment in loci with
a threshold p < 0.01 for eight GWAS traits: lipid
levels (TG, HDL, LDL), body mass index (BMI),
waist hip ratio corrected for BMI (WHR), T2D,
coronary heart disease (CHD), and systolic blood
pressure (SBP). *Chi-square p < 0.00625, signifi-
cance threshold with Bonferroni correction for
multiple testing of eight traits.
(B) One HDL-associated PPARg motif-altering
SNP (rs392794) fell 300 kb from the ANKRD55
gene, with the T allele giving a stronger motif.
(C) Luciferase reporters with the T and C alleles at
this SNP were transiently transfected into 293T
cells with or without expression plasmids for
PPARg and RXRa, and the T allele reporter gave
higher PPARg-dependent activity (mean and SD;
*p < 0.01 by unpaired t test, two-tailed).
(D) Locus zoom plot showing this SNP has a
genome-wide significant association with HDL,
and it was not linked to the nearby previously
described lipid association at SNP rs9686661,
with a low r2 value and a recombination hot spot
(red arrow) between the SNPs.
(E) In addition to the HDL association (orange), this
SNP had significant associations with other meta-
bolic traits (p < 0.005 in green). Associations for
rs392794 are via the near perfect proxy rs459193
(r2 = 0.957) which was genotyped in the GWAS.PPARgmotif-altering SNP maintained a strong independent as-
sociation with HDL (p = 3.3e-06). In addition to HDL, this PPARg
motif-altering SNP rs392794 was also found to be associated
with other metabolic traits, including serum TG, waist-hip ratio,
and systolic blood pressure (Figure 7E). Thus, PPARg occu-
pancy and transcriptional activity at this site in human WAT
may provide the mechanism for association with multiple traits
that are part of the metabolic syndrome (Grundy et al., 2004).
DISCUSSION
Non-coding regulatory variants are key to understanding differ-
ences among individuals. Here, we show that SNPs affect TF
genomic occupancy, gene expression, and drug response in
adipose tissue. Moreover, PPARg site SNPs in human fat may
modulate genetic risk of metabolic disease.
Previous studies have shown that TF binding among mamma-
lian species differs in numerous cases even when the motif is
intact (Mikkelsen et al., 2010; Schmidt et al., 2010; Soccio
et al., 2011), and many are accounted for by variants affecting
co-bound TFs (Schmidt et al., 2011; Stefflova et al., 2013).
Here, we show that this applies within a species, as SNPs affect
PPARg occupancy in WAT by altering motifs for PPARg itself or
other cooperating TFs. A similar phenomenon was reported in
macrophages from inbred mouse strains, where SNPs altering
PU.1 motifs and binding also affected binding of C/EBPa and
vice versa (Heinz et al., 2013). The mechanism likely involves
cooperativity by assisted loading, which has been shown for re-
combinant PPARg and C/EBPa in immortalized cell lines (Mad-sen et al., 2014). The present study demonstrates that these prin-
ciples apply in living tissues in mice and man.
Motif-altering SNPs accounted for 20% of strain-selective
PPARg binding between two mouse strains, even when only
the top four TF motifs in PPARg binding regions were consid-
ered. The majority of SNPs in strain-selective sites failed to alter
recognizable motifs, consistent with a recent report that GWAS
causal variant SNPs are highly enriched in tissue-specific en-
hancers, yet only 10%–20% directly alter motifs, while most
are ‘‘motif adjacent’’ (Farh et al., 2015). There was also clear
strain-selective binding at non-polymorphic PPARg sites, and
we provide evidence for a novel mechanism based on the
observed clustering of strain-selective sites: a causal polymor-
phic site may drive differential binding at other sites by long-
range interactions within a regulatory locus. Conversely, we
observed numerous cases of motif-altering SNPs that failed to
give strain-selective PPARg binding, consistent with prior re-
ports and presumably attributable to factors such as specific
motif alterations, distance to peak center, presence of alterna-
tive motifs, and ‘‘buffering’’ by site context (Heinz et al., 2013;
Maurano et al., 2012).
We found many examples in which genes nearest to mouse
strain-selective PPARg sites showed differential expression,
and this enrichment was evident genome wide for basal or rosi-
glitazone-induced adipose gene expression. The consistent di-
rection of PPARg occupancy and gene regulation effects (i.e.,
B6-stronger motif SNPswith B6-selective binding and B6-higher
gene expression) argues strongly for causality. Similarly in hu-
mans, motif-altering PPARg site SNPs showed enrichment forCell 162, 33–44, July 2, 2015 ª2015 Elsevier Inc. 41
eQTLs in the predicted direction. Our approach used SNPs as
‘‘experiments of nature’’ to identify candidate functional binding
sites among themultitude of sites that surround some genes, but
further experiments will be necessary to elucidate the mecha-
nisms underlying ‘‘functional’’ versus ‘‘non-functional’’ binding
events, which is a major unanswered question in the field and
may involve enhancer activity and/or 3D-looping events. Indeed,
the majority of strain-selective sites did not have a detectable ef-
fect on the nearest expressed gene (though the actual targets
may be more distant). Apparently non-functional regulatory vari-
ation may result from multiplicity and redundancy of enhancers
around target genes (Cusanovich et al., 2014), as adipocyte
gene expression has been correlated with the number of nearby
PPARg sites (Step et al., 2014). Just as PPARg regulatory varia-
tion is not always functional, only a subset of differential genes
are explained by PPARg regulatory variation, as myriad other
factors could affect adipose gene expression or response to
TZD—yet our genome-wide methods had the power to identify
the important cases of functional regulatory variation.
In addition to regulating basal adipose tissue gene expression,
genetic variation at PPARg sites also determines response to
PPARg ligand rosiglitazone. While there were more strain-selec-
tive TZD-induced genes than could be accounted for by PPARg
sites and thus other strain effects drive some of the observed
variability in drug response, genetically determined differential
PPARg binding emerged as a clear mechanism for some
strain-selective rosiglitazone effects. This provides proof of
concept that naturally occurring genetic variation can affect nu-
clear receptor ligand-mediated gene activation and,more gener-
ally, drug response in living animals. This has special significance
for TZDs, which have powerful anti-diabetic effects but limited
clinical utility due to adverse effects, including bone loss and
edema (Soccio et al., 2014). The target genes responsible for
TZD efficacy and side effects are unknown, but genetically
determined differences in TZD activation of such genes may un-
derlie inter-individual differences in drug response. PPARg cis-
tromes are cell type specific (Lefterova et al., 2010), and thus a
given SNP might differentially impact the therapeutic and harm-
ful effects of TZDs, particularly sincemany TZD side effects likely
reflect non-adipose tissues. Understanding regulatory variation
could lead to personalized PPARg agonist therapy based upon
individual profiles of SNPs that alter PPARg binding.
There is great potential linking regulatory variation to human
genetics of disease susceptibility revealed by GWAS. A recent
effort to identify causal GWAS SNPs and their tissue effects
showed that SNPs affecting TG and HDL fell in enhancers from
adipose tissue (Farh et al., 2015). The present work shines a
bright light on the role of PPARg in this context, as the polymor-
phic PPARg sites that we identified in human fat were enriched
for the same dyslipidemic GWAS traits.
Detailed study of one PPARgmotif-altering SNP, rs392794, re-
vealed its association with several metabolic syndrome traits. Of
note, in GWAS meta-analyses, a near-perfect proxy (rs459193)
has been identified as the lead SNP in finely mapped loci for
both T2D (Morris et al., 2012) and waist-hip ratio (Shungin
et al., 2015). Thus, the PPARg site SNP identified here could
be responsible for these associations with T2D and visceral
adiposity, as well as the other metabolic traits reported here.42 Cell 162, 33–44, July 2, 2015 ª2015 Elsevier Inc.While the GWAS locus is named for ANKRD55, this gene is quite
distant (TSS 279 kb away) and is not expressed in adipose tis-
sue, and we were unable to link the metabolism-associated
PPARg site to ANKRD55 or any other gene. Thus, the target
gene for this PPARg-bound enhancer and theGWASeffect is un-
known, and further studies will be necessary to understand how
differential SNP-dependent PPARg occupancy at this site may
alter systemic metabolic phenotypes.
In sum, SNPs affect adipose PPARg genomic occupancy and
the basal and drug-induced expression of nearby genes. SNPs
that alter PPARg binding are enriched in loci affecting metabolic
traits, such that they contribute to an individual’s metabolic dis-
ease risk. They also impact personalized pharmacogenomics, as
better understanding of the tissue-specific functions of such
SNPs has the potential to improve the risk/benefit ratio for TZD
therapy in individual patients based on their genomes. The impli-
cations of this work go beyond PPARg to all drug targets that
function directly at the genome to regulate physiology in health
and disease.
EXPERIMENTAL PROCEDURES
Mouse and Human Adipose Tissue Samples
Male wild-type inbred C57Bl/6J and 129S1/SvImJ mice, in addition to the F1
intercross progeny (B6129SF1/J), were purchased from Jackson Labora-
tories, and all care and use procedures were approved by the Institutional An-
imal Care and Use Committee of the University of Pennsylvania. Human fat
samples (Table S3) were obtained from the Human Adipose Resource (HAR)
of the Penn Institute for Diabetes, Obesity, and Metabolism, which obtains
pre-operative informed consent from surgical patients for biopsies to be taken,
banked, and distributed to investigators with de-identified patient characteris-
tics. All HAR protocols were approved by the University of Pennsylvania’s
Institutional Review Board.
ChIP-Seq, RNA-Seq, and GRO-Seq
Three related experiments compared PPARgChIP-seq inWAT frommalemice
of the B6 and 129 strains, with minor differences in age, depot (epididymal
versus inguinal), and diet (chow versus low fat control diet, Table S1). The great
concordance among the three experiments allowed high-confidence identifi-
cation of genetic effects. The 5.3 million known SNPs differing between B6
and 129 mice (Keane et al., 2011) were incorporated into SNP-sensitive
GSNAP read alignments (Wu and Nacu, 2010). The HOMER software suite
(Heinz et al., 2010) was used for peak identification and quantification. Motif
identification and determination of SNP effects on motifs was performed as
described in the Supplemental Experimental Procedures. Four related exper-
iments compared WAT RNA-seq from male mice of the B6 and 129 strains,
with one also measuring the effect of rosiglitazone treatment for 2 weeks
(Table S2). GRO-seq was performed, and eRNAs were identified and quanti-
tated as previously described (Fang et al., 2014), with minor modifications
for mouse WAT samples. All deep sequencing (single-end 50 or 100 bp reads)
was performed by the Functional Genomics Core of the Penn Diabetes
Research Center using Illumina HiSeq2000 and the Solexa Analysis Pipeline.
Allelic imbalance was assayed in aligned sequence read BAM files using an
allele counting PERL script.
Other Methods
Quantitative PCR was performed using ABI 7500 Fast Real-Time PCR System
and Power SYBR Green PCR Master Mix (Applied Biosystems). Allelic imbal-
ance was confirmed at individual loci using the SNaPshot assay (Applied Bio-
systems). See Supplemental Experimental Procedures.
Statistical Methods
Prism (Graphpad) was used for graphing and statistical tests, all of which are
described in figure legends.
ACCESSION NUMBERS
All ChIP-seq, RNA-seq, and GRO-seq data reported here have been depos-
ited in GEO with accession numbers GEO: GSE64458, GSE64459, and
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